Janux Therapeutics, Inc. (JANX) is a biotechnology company focused on developing novel immunotherapies for the treatment of cancer. Technical analysis plays a crucial role in evaluating the stock's performance and identifying potential trends. By analyzing various technical indicators, investors can gain valuable insights into the stock's price movements. Let's take a look at some key technical indicators for JANX.

The Relative Strength Index (RSI) is a popular momentum oscillator that measures the speed and change of price movements. It ranges from 0 to 100 and is often used to determine overbought or oversold conditions. JANX stock's RSI is an essential indicator that provides insights into its price strength and helps identify potential trend reversals.

Janux Therapeutics (JANX) Technical Analysis

Technical analysis indicators for Janux Therapeutics, Inc. (JANX) stock, including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Get insights into the stock's performance without any call to actions or promotional language. Discover how these indicators can help assess the stock's trends and momentum.

Janux Therapeutics, Inc. (JANX) Technical Analysis: Indicators, RSI, ADX, MACD, ROC, STOCHRSI, WILLR

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.

Janux Therapeutics

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	39.39	Neutral	24.3%
auto_graphMACD	-8.72	Neutral	-17.8%
auto_graphCCI	-140.35	Buy	23.6%
auto_graphADX	15.13	Neutral	27.0%
auto_graphATR	14.79	Buy	-
auto_graphWILLR	-68.89	Neutral	10.7%
auto_graphROC	-11.87	Neutral	33.9%
auto_graphSTOCHRSI	0.00	Buy	124.5%

Buy	3	-62.50%
Hold	5	-37.50%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Janux Therapeutics (JANX) Technical Analysis

Keep an eye on Janux Therapeutics

Frequently Asked Questions

What are the technical signals for Janux Therapeutics (JANX) stock based on the last 30 days?

Take Your Investments to a Whole New Level